Skin Laxity
Conditions
Brief summary
Evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening
Interventions
Fractional ablative laser used for treatment for skin laxity and tightening
Sponsors
Sciton
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female subjects aged 18-85 years 2. Fitzpatrick skin type I-VI 3. Has visible skin laxity in the treatment region or has a scar 4. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (Applicable to female subjects only) 5. Willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes 6. Subject must be able to read, understand and sign Informed Consent Form in English 7. Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions
Exclusion criteria
1. Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study. 2. Any type of prior cosmetic treatment to the target area at physicians' discretion 3. History of malignant tumors in the target area. 4. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles. 5. Pregnant and/or breastfeeding (Applicable to females only) 6. Having an infection, dermatitis or a rash in the treatment area. 7. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders. 8. Suffering from coagulation disorders or taking prescription anticoagulation medications. 9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing. 10. History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. 11. History of vitiligo, eczema, or psoriasis. 12. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen. 13. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. 14. Current smoker or history of smoking within 6 months of study participation. 15. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Wrinkles | 1-6 months post final treatment | Percent improvement in wrinkles will be assessed using digital camera at baseline and post final treatment. |
Countries
United States
Contacts
Primary ContactSciton Inc.
Backup ContactSciton Inc
Outcome results
None listed